Cha, Eunji Kim, Hak Joong Lim, Sang Min 2024-01-19T08:31:27Z 2024-01-19T08:31:27Z 2023-11-08 2024-01 0253-2964 https://pubs.kist.re.kr/handle/201004/113177 Tauopathy is characterized by the abnormal aggregation of tau proteins. In order to develop drugs for tauopathies, a variety of different therapeutic strategies have been investigated. Synapse loss is a hallmark of tauopathies and is reportedly related to cognitive impairment in Alzheimer's disease as well. Emerging evidence suggests that pathogenic tau species are linked to synaptic dysfunction and synapse loss in tauopathies. As such, a potential therapeutic approach to ameliorate synaptic dysfunction and counteract synaptic loss due to pathogenic tau holds promise. This review highlights the pathological links between tau pathology and synaptic integrity and current efforts to develop therapeutics rescuing synaptic dysfunction for tauopathies, which will help to understand the association between tau and synapses and develop disease-modifying drugs for tauopathies. English 대한화학회 Insights to develop tau-directed therapeutics to protect the synaptic integrity for tauopathies Article 10.1002/bkcs.12792 1 Bulletin of the Korean Chemical Society, v.45, no.1, pp.45 - 54 Bulletin of the Korean Chemical Society 45 1 45 54 N scie kci ART003046456 001086018600001 2-s2.0-85174223230 Chemistry, Multidisciplinary Chemistry Review MILD COGNITIVE IMPAIRMENT ALZHEIMERS-DISEASE AMYLOID-BETA ALLOSTERIC MODULATOR ELECTRICAL SYNAPSES PATHOLOGICAL TAU VESICLE PROTEIN ACETYLATED TAU OLIGOMERS DYSFUNCTION synapse synaptic dysfunction tau tauopathy therapeutics